<DOC>
	<DOCNO>NCT01239992</DOCNO>
	<brief_summary>The study design evaluate effect Niacin/Laropiprant postprandial lipoprotein metabolism , postprandial glucose metabolism , postprandial monocyte function , postprandial biomarkers endothelial dysfunction inflammation .</brief_summary>
	<brief_title>Effect Niacin/Laropiprant Postprandial Lipoprotein Metabolism Patients With Dyslipoproteinemia</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Male subject postmenopausal female subject age 1970 year High risk patient ( PROCAM risk ≥20 % ) stable statintherapy , least simvastatin 20 mg/d HDLcholesterol ≤50 mg/dl /or triglycerides 150400 mg/dl and/or LDLcholesterol 70 150 mg/dl Lipoprotein ( ) &lt; 30 mg/dl Patients may normal glucose metabolism ( normal HOMA ) , insulin resistant ( abnormal HOMA ) , impaired fast glucose impair glucose tolerance diabetes mellitus . Without niacin therapy least 6 month Dosage concomitant medication stable least 3 week If female , postmenopausal ( absence menstruation least 12 month absence menstruation &gt; 6 month FSH &gt; 40 ng/ml respectively oestrogen &lt; 20 pg/ml ) Subjects additional cause hyperlipoproteinemia Diabetes mellitus antidiabetic medication Subject history cardiovascular ischemia previous 3 month acute myocardial infarction unstable angina History psychiatric disorder cognitive impairment would interfere participation study History alcoholism Contraindication niacin and/or laropiprant Subject participate investigational study within 30 day prior study initiation Fasting triglycerides &gt; 400 mg/dl Lifethreatening disease ( e.g . cancer ) Renal insufficiency ( GFR ≤ 30 ml/min ) Major hepatic impairment Known allergic reaction/intolerance niacin and/or laropiprant Active peptic ulcer disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>